Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia
Authors
Keywords
-
Journal
Stem Cells Translational Medicine
Volume 11, Issue 5, Pages 461-477
Publisher
Oxford University Press (OUP)
Online
2022-03-08
DOI
10.1093/stcltm/szac015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MRD Tailored Therapy in AML: What We Have Learned So Far
- (2021) Lok Lam Ngai et al. Frontiers in Oncology
- Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan
- (2021) Masamichi Isobe et al. ANNALS OF HEMATOLOGY
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
- (2021) Thomas Cluzeau et al. JOURNAL OF CLINICAL ONCOLOGY
- HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis
- (2021) Mahasweta Gooptu et al. BLOOD
- Emerging agents and regimens for AML
- (2021) Hongtao Liu Journal of Hematology & Oncology
- Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
- (2021) Maria H. Gilleece et al. Blood Cancer Journal
- Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling
- (2021) Adrián Mosquera Orgueira et al. Frontiers in Oncology
- Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML
- (2021) Firas El Chaer et al. Blood Advances
- The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update
- (2021) Xiao-hui Zhang et al. Journal of Hematology & Oncology
- Serial frailty assessments following allogeneic stem cell transplant in older adults: A pilot study
- (2021) Rachel Ombres et al. Journal of Geriatric Oncology
- The Simplified Comorbidity Index (SCI) - a new tool for prediction of non-relapse mortality in allogeneic HCT
- (2021) Roni Shouval et al. Blood Advances
- Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial
- (2021) Nigel H Russell et al. HAEMATOLOGICA
- Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
- (2021) Lorenzo Canti et al. Journal of Hematology & Oncology
- Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care
- (2021) Vanessa E Kennedy et al. Lancet Haematology
- Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
- (2021) Jacqueline S. Garcia et al. Blood Advances
- Validation of a Hematopoietic Cell Transplant - Composite Risk (HCT-CR) Model for Post Transplant Survival Prediction in Patients with Hematologic Malignancies
- (2020) Stefan O. Ciurea et al. CLINICAL CANCER RESEARCH
- Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?
- (2020) Felicetto Ferrara et al. Expert Review of Hematology
- Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: Long‐term follow up of a phase III study
- (2020) Frédéric Baron et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of detectable measurable residual disease on umbilical cord blood transplantation
- (2020) Frédéric Baron et al. AMERICAN JOURNAL OF HEMATOLOGY
- How we treat older patients with acute myeloid leukaemia
- (2020) Avraham Frisch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2020) Ali Bazarbachi et al. HAEMATOLOGICA
- Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT
- (2020) Jaime Sanz et al. Journal of Hematology & Oncology
- Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
- (2020) Maria C.B. Bittencourt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT
- (2020) Arnon Nagler et al. BONE MARROW TRANSPLANTATION
- AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy
- (2020) Bowen Yan et al. EXPERIMENTAL HEMATOLOGY
- Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide
- (2020) Laura Solán et al. HEMATOLOGICAL ONCOLOGY
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101)
- (2020) Ephraim J Fuchs et al. BLOOD
- How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation
- (2020) Benoît Vandenhove et al. Frontiers in Immunology
- Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
- (2020) Linde M. Morsink et al. Cancers
- Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects
- (2020) Jan-Niklas Eckardt et al. Blood Advances
- GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
- (2019) Francesca Bonifazi et al. Lancet Haematology
- Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
- (2019) Javier Bolaños-Meade et al. Lancet Haematology
- Cellular therapy for acute myeloid Leukemia – Current status and future prospects
- (2019) Panupong Hansrivijit et al. BLOOD REVIEWS
- Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application
- (2019) Riad El Fakih et al. BONE MARROW TRANSPLANTATION
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
- (2019) Celalettin Ustun et al. LEUKEMIA
- Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification
- (2019) Mohamed L. Sorror et al. JAMA Oncology
- Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience
- (2019) Maël Heiblig et al. Cancers
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2019) Olle Ringdén et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2019) Avichai Shimoni et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Decitabine compared with conventional regimens in older patients with acute myeloid leukemia: A meta-analysis
- (2019) Mei-Ru Bian et al. Clinical Lymphoma Myeloma & Leukemia
- Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
- (2019) Sarah Bertoli et al. Cancer Medicine
- Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies
- (2019) Luiza Handschuh Journal of Oncology
- Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation
- (2019) Philip H. Imus et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation
- (2019) Piyanuch Kongtim et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?
- (2019) Takafumi Shichijo et al. BONE MARROW TRANSPLANTATION
- Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies
- (2019) Richard J. Lin et al. BONE MARROW TRANSPLANTATION
- EASIX and mortality after allogeneic stem cell transplantation
- (2019) Thomas Luft et al. BONE MARROW TRANSPLANTATION
- Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
- (2019) Frédéric Baron et al. HAEMATOLOGICA
- The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population‐based study
- (2019) Xingnong Ye et al. HEMATOLOGICAL ONCOLOGY
- Acute myeloid leukaemia and the immune system: implications for immunotherapy
- (2019) A. John Barrett BRITISH JOURNAL OF HAEMATOLOGY
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding
- (2019) Natalia S. Nunes et al. Frontiers in Immunology
- Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
- (2019) Stefan O. Ciurea et al. BLOOD
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
- (2019) Christopher S. Hourigan et al. JOURNAL OF CLINICAL ONCOLOGY
- Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu
- (2018) Maria H Gilleece et al. AMERICAN JOURNAL OF HEMATOLOGY
- Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
- (2018) Stefan O. Ciurea et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation
- (2018) Raynier Devillier et al. BONE MARROW TRANSPLANTATION
- Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen
- (2018) Frédéric Baron et al. CLINICAL CANCER RESEARCH
- Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged ≥ 75 years
- (2018) Victoria V. Prassek et al. HAEMATOLOGICA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged ≥ 75 years
- (2018) Victoria V. Prassek et al. HAEMATOLOGICA
- Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
- (2018) Jodi Lipof et al. Cancers
- Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2018) Catherine J. Lee et al. BONE MARROW TRANSPLANTATION
- Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome
- (2018) Piyanuch Kongtim et al. BONE MARROW TRANSPLANTATION
- Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia
- (2018) Chong Gao et al. MEDICINE
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia
- (2018) Rebecca Levin-Epstein et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
- (2018) Uwe Platzbecker et al. LANCET ONCOLOGY
- Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2017) Bart L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
- (2017) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects
- (2017) Grégory Ehx et al. OncoImmunology
- Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
- (2017) Mohamed L. Sorror et al. JAMA Oncology
- Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia
- (2016) Jun Aoki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years
- (2016) Karamjeet S. Sandhu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing
- (2016) Moussab Damlaj et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis
- (2016) Armin Rashidi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
- (2016) Irwin Walker et al. LANCET ONCOLOGY
- Cord-Blood Transplantation in Patients with Minimal Residual Disease
- (2016) Filippo Milano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study
- (2016) Roni Shouval et al. PLoS One
- Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients
- (2015) F. Buccisano et al. ANNALS OF HEMATOLOGY
- Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation
- (2015) Betül Oran et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
- (2015) Steven M. Devine et al. JOURNAL OF CLINICAL ONCOLOGY
- Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
- (2015) Alessandro Rambaldi et al. LANCET ONCOLOGY
- Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
- (2015) Jurjen Versluis et al. Lancet Haematology
- Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics
- (2015) H. Joachim Deeg et al. JAMA Oncology
- Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–Matched Unrelated and Related Donors
- (2014) Antonio Di Stasi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow Transplant Research-Eurocord Analysis
- (2014) Daniel Weisdorf et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- “To Combine or Not to Combine:” Optimizing Risk Assessment before Allogeneic Hematopoietic Cell Transplantation
- (2014) Mahmoud ElSawy et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
- (2014) Boglarka Gyurkocza et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation
- (2014) H-t Wang et al. BONE MARROW TRANSPLANTATION
- Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation
- (2014) B K Hamilton et al. BONE MARROW TRANSPLANTATION
- Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2014) Frédéric Baron et al. CANCER
- Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients
- (2014) L. S. Muffly et al. HAEMATOLOGICA
- Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
- (2014) Mohamed L. Sorror et al. JOURNAL OF CLINICAL ONCOLOGY
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome of older patients with acute myeloid leukemia
- (2013) Mya S. Thein et al. CANCER
- Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification
- (2013) M. Wetzler et al. HAEMATOLOGICA
- Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia
- (2013) Mohamed L Sorror et al. Expert Review of Hematology
- Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome
- (2012) N. Kroger BLOOD
- Acute myeloid leukemia in the real world: why population-based registries are needed
- (2012) G. Juliusson et al. BLOOD
- Survival for older patients with acute myeloid leukemia: a population-based study
- (2012) B. Oran et al. HAEMATOLOGICA
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
- (2012) Martin Bornhäuser et al. LANCET ONCOLOGY
- Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
- (2011) Sherif S. Farag et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities
- (2011) A. Perrot et al. BLOOD
- Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation
- (2011) M. Fang et al. BLOOD
- Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius
- (2011) G. Socie et al. BLOOD
- Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike
- (2011) I Danylesko et al. BONE MARROW TRANSPLANTATION
- Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors
- (2011) N S Majhail et al. BONE MARROW TRANSPLANTATION
- Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score
- (2011) Martine Extermann et al. CANCER
- Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
- (2011) Mohamed L. Sorror et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience
- (2010) B. C. Medeiros et al. BLOOD
- Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns
- (2010) F. L. Wong et al. BLOOD
- FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
- (2010) S. P. Whitman et al. BLOOD
- Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
- (2010) Brian L. McClune et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk score for outcome after allogeneic hematopoietic stem cell transplantation
- (2009) Alois Gratwohl et al. CANCER
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
- (2009) Benjamin D. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
- (2009) Heiko Becker et al. JOURNAL OF CLINICAL ONCOLOGY
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
- Quality of life and social integration after allogeneic hematopoietic SCT
- (2008) S Bieri et al. BONE MARROW TRANSPLANTATION
- Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group
- (2008) Johannes Schetelig et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720
- (2008) Maria R. Baer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now